First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors
Ameratunga, M Harvey, RD Mau-Sorensen, M Thistlethwaite, Fiona C Forssmann, U Gupta, M Johannsdottir, H Ramirez-Andersen, T Bohlbro, ML Losic, N
Ameratunga, M
Harvey, RD
Mau-Sorensen, M
Thistlethwaite, Fiona C
Forssmann, U
Gupta, M
Johannsdottir, H
Ramirez-Andersen, T
Bohlbro, ML
Losic, N
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Ameratunga M, Harvey RD, Mau-S�rensen M, Thistlethwaite F, Forssmann U, Gupta M, et al. First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors. J Clin Oncol. 2019;37(15_suppl):2525-.